vs

Side-by-side financial comparison of Antero Midstream Corp (AM) and PHIBRO ANIMAL HEALTH CORP (PAHC). Click either name above to swap in a different company.

PHIBRO ANIMAL HEALTH CORP is the larger business by last-quarter revenue ($373.9M vs $297.0M, roughly 1.3× Antero Midstream Corp). Antero Midstream Corp runs the higher net margin — 17.5% vs 7.3%, a 10.1% gap on every dollar of revenue. On growth, PHIBRO ANIMAL HEALTH CORP posted the faster year-over-year revenue change (20.9% vs 3.3%). Over the past eight quarters, PHIBRO ANIMAL HEALTH CORP's revenue compounded faster (19.2% CAGR vs 3.2%).

Antero Resources Corporation is an American company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in Denver, Colorado. The company's reserves are entirely in the Appalachian Basin and are extracted using hydraulic fracturing.

Phibro Animal Health Corporation is an American animal health and mineral nutrition company. Its products include antibacterials, anticoccidials, anthelmintics, as well as animal nutrition and vaccines for livestock. The company operates through three segments Mineral Nutrition, Performance Materials, and Animal Health, from which most of its revenue is derived. The company operates in the United States, Latin America, Canada, Europe, Middle East, Africa, and Asia-Pacific. It is incorporated ...

AM vs PAHC — Head-to-Head

Bigger by revenue
PAHC
PAHC
1.3× larger
PAHC
$373.9M
$297.0M
AM
Growing faster (revenue YoY)
PAHC
PAHC
+17.6% gap
PAHC
20.9%
3.3%
AM
Higher net margin
AM
AM
10.1% more per $
AM
17.5%
7.3%
PAHC
Faster 2-yr revenue CAGR
PAHC
PAHC
Annualised
PAHC
19.2%
3.2%
AM

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
AM
AM
PAHC
PAHC
Revenue
$297.0M
$373.9M
Net Profit
$51.9M
$27.5M
Gross Margin
35.5%
Operating Margin
33.8%
13.5%
Net Margin
17.5%
7.3%
Revenue YoY
3.3%
20.9%
Net Profit YoY
-53.3%
762.1%
EPS (diluted)
$0.11
$0.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AM
AM
PAHC
PAHC
Q4 25
$297.0M
$373.9M
Q3 25
$294.8M
$363.9M
Q2 25
$305.5M
$378.7M
Q1 25
$291.1M
$347.8M
Q4 24
$287.5M
$309.3M
Q3 24
$269.9M
$260.4M
Q2 24
$269.8M
$273.2M
Q1 24
$279.1M
$263.2M
Net Profit
AM
AM
PAHC
PAHC
Q4 25
$51.9M
$27.5M
Q3 25
$116.0M
$26.5M
Q2 25
$124.5M
$17.2M
Q1 25
$120.7M
$20.9M
Q4 24
$111.2M
$3.2M
Q3 24
$99.7M
$7.0M
Q2 24
$86.0M
$752.0K
Q1 24
$103.9M
$8.4M
Gross Margin
AM
AM
PAHC
PAHC
Q4 25
35.5%
Q3 25
32.9%
Q2 25
29.0%
Q1 25
30.1%
Q4 24
32.9%
Q3 24
32.1%
Q2 24
31.9%
Q1 24
30.2%
Operating Margin
AM
AM
PAHC
PAHC
Q4 25
33.8%
13.5%
Q3 25
61.2%
14.1%
Q2 25
61.0%
8.9%
Q1 25
60.9%
9.6%
Q4 24
61.8%
8.3%
Q3 24
60.2%
6.8%
Q2 24
56.6%
6.7%
Q1 24
59.6%
7.6%
Net Margin
AM
AM
PAHC
PAHC
Q4 25
17.5%
7.3%
Q3 25
39.3%
7.3%
Q2 25
40.8%
4.5%
Q1 25
41.5%
6.0%
Q4 24
38.7%
1.0%
Q3 24
37.0%
2.7%
Q2 24
31.9%
0.3%
Q1 24
37.2%
3.2%
EPS (diluted)
AM
AM
PAHC
PAHC
Q4 25
$0.11
$0.67
Q3 25
$0.24
$0.65
Q2 25
$0.26
$0.43
Q1 25
$0.25
$0.51
Q4 24
$0.23
$0.08
Q3 24
$0.21
$0.17
Q2 24
$0.18
$0.02
Q1 24
$0.21
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AM
AM
PAHC
PAHC
Cash + ST InvestmentsLiquidity on hand
$180.4M
$74.5M
Total DebtLower is stronger
$3.2B
$624.2M
Stockholders' EquityBook value
$2.0B
$332.4M
Total Assets
$5.9B
$1.4B
Debt / EquityLower = less leverage
1.63×
1.88×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AM
AM
PAHC
PAHC
Q4 25
$180.4M
$74.5M
Q3 25
$85.3M
Q2 25
$77.0M
Q1 25
$70.4M
Q4 24
$67.1M
Q3 24
$89.8M
Q2 24
$114.6M
Q1 24
$26.1M
$98.7M
Total Debt
AM
AM
PAHC
PAHC
Q4 25
$3.2B
$624.2M
Q3 25
$3.0B
$628.0M
Q2 25
$3.0B
$631.7M
Q1 25
$3.1B
$635.4M
Q4 24
$3.1B
$639.1M
Q3 24
$3.2B
$295.2M
Q2 24
$3.2B
$312.1M
Q1 24
$3.2B
Stockholders' Equity
AM
AM
PAHC
PAHC
Q4 25
$2.0B
$332.4M
Q3 25
$2.1B
$311.7M
Q2 25
$2.1B
$285.7M
Q1 25
$2.1B
$266.0M
Q4 24
$2.1B
$246.8M
Q3 24
$2.1B
$258.5M
Q2 24
$2.1B
$256.6M
Q1 24
$2.2B
$270.1M
Total Assets
AM
AM
PAHC
PAHC
Q4 25
$5.9B
$1.4B
Q3 25
$5.7B
$1.4B
Q2 25
$5.7B
$1.4B
Q1 25
$5.8B
$1.3B
Q4 24
$5.8B
$1.3B
Q3 24
$5.8B
$966.3M
Q2 24
$5.8B
$982.2M
Q1 24
$5.7B
$979.0M
Debt / Equity
AM
AM
PAHC
PAHC
Q4 25
1.63×
1.88×
Q3 25
1.46×
2.01×
Q2 25
1.45×
2.21×
Q1 25
1.49×
2.39×
Q4 24
1.47×
2.59×
Q3 24
1.49×
1.14×
Q2 24
1.50×
1.22×
Q1 24
1.48×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AM
AM
PAHC
PAHC
Operating Cash FlowLast quarter
$255.5M
$19.4M
Free Cash FlowOCF − Capex
$8.3M
FCF MarginFCF / Revenue
2.2%
Capex IntensityCapex / Revenue
3.0%
Cash ConversionOCF / Net Profit
4.92×
0.70×
TTM Free Cash FlowTrailing 4 quarters
$47.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AM
AM
PAHC
PAHC
Q4 25
$255.5M
$19.4M
Q3 25
$212.8M
$9.3M
Q2 25
$265.2M
$21.3M
Q1 25
$198.9M
$43.2M
Q4 24
$232.7M
$3.1M
Q3 24
$184.9M
$12.6M
Q2 24
$215.8M
$28.4M
Q1 24
$210.6M
$11.4M
Free Cash Flow
AM
AM
PAHC
PAHC
Q4 25
$8.3M
Q3 25
$-4.5M
Q2 25
$8.1M
Q1 25
$35.4M
Q4 24
$-4.7M
Q3 24
$184.3M
$3.0M
Q2 24
$147.2M
$15.4M
Q1 24
$208.5M
$1.7M
FCF Margin
AM
AM
PAHC
PAHC
Q4 25
2.2%
Q3 25
-1.2%
Q2 25
2.1%
Q1 25
10.2%
Q4 24
-1.5%
Q3 24
68.3%
1.2%
Q2 24
54.6%
5.6%
Q1 24
74.7%
0.6%
Capex Intensity
AM
AM
PAHC
PAHC
Q4 25
3.0%
Q3 25
3.8%
Q2 25
3.5%
Q1 25
2.2%
Q4 24
0.0%
2.5%
Q3 24
0.2%
3.7%
Q2 24
25.4%
4.8%
Q1 24
0.7%
3.7%
Cash Conversion
AM
AM
PAHC
PAHC
Q4 25
4.92×
0.70×
Q3 25
1.84×
0.35×
Q2 25
2.13×
1.24×
Q1 25
1.65×
2.07×
Q4 24
2.09×
0.97×
Q3 24
1.85×
1.81×
Q2 24
2.51×
37.80×
Q1 24
2.03×
1.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AM
AM

Gathering Low Pressure$114.2M38%
Natural Gas Water Handling And Treatment Affiliate$63.2M21%
Water Handling$55.7M19%
Fresh Water Delivery$37.2M13%
Other Fluid Handling$26.9M9%

PAHC
PAHC

Medicated Feed Additives And Others$202.1M54%
Mineral Nutrition$68.9M18%
Nutritional Specialties$50.2M13%
Vaccines$37.6M10%
Performance Products$15.0M4%

Related Comparisons